The Pathobiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: The Case for Neuroglial Failure.
Renz-Polster, Herbert, Tremblay, Marie-Eve, Bienzle, Dorothee et al. · Frontiers in cellular neuroscience · 2022 · DOI
Quick Summary
This study suggests that ME/CFS might be caused by problems with certain support cells in the brain called glia, which help protect and maintain nerve cells. The researchers reviewed existing research on two key ME/CFS symptoms—feeling worse after activity and reduced blood flow to the brain—and found evidence that brain cell dysfunction could explain many of the different problems seen in ME/CFS.
Why It Matters
This hypothesis offers a potentially unifying framework for understanding ME/CFS's complex, multisystem pathology, which has historically been fragmented across competing mechanisms. If neuroglial dysfunction is indeed central to ME/CFS, it could redirect research and therapeutic development toward novel treatments targeting brain glial cells. The proposal that similar mechanisms may apply to long COVID could accelerate understanding of both conditions.
Observed Findings
Post-exertional malaise and cerebral hypoperfusion are recognized cardinal features of ME/CFS with consistent clinical profiles
Multiple distinct pathological pathways (immune, inflammatory, mitochondrial, cardiovascular, neurological) have been identified in ME/CFS research
Similar patterns of PEM and cerebral blood flow abnormalities have been observed in subsets of post-COVID patients
Neuroglial cells (astrocytes, microglia, oligodendrocytes) have established roles in regulating cerebral blood flow, energy metabolism, and neuroinflammation
Inferred Conclusions
Neuroglial dysfunction may serve as a common denominator linking diverse pathobiological pathways in ME/CFS
Dysfunction of glial cells could mechanistically explain both post-exertional malaise and cerebral hypoperfusion
The neuroglial dysfunction hypothesis may apply to post-acute COVID syndrome given overlapping clinical features
Target investigation of central nervous system glial pathology could advance understanding of ME/CFS pathobiology
Remaining Questions
Do ME/CFS patients show direct evidence of abnormal glial cell structure or function compared to healthy controls?
Which specific glial cell dysfunctions (astrocytic, microglial, or oligodendrocytic) are most central to PEM and cerebral hypoperfusion?
What This Study Does Not Prove
This review-based mechanistic study does not provide direct evidence that glial dysfunction actually occurs in ME/CFS patients—it synthesizes existing literature to propose a hypothesis. The study cannot prove causation or establish whether glial problems are primary drivers or secondary consequences of other pathological processes. It does not test whether correcting glial dysfunction would improve symptoms.